Autoimmune Hepatitis

Understanding Autoimmune Hepatitis

Autoimmune hepatitis is a chronic inflammatory liver disease in which your immune system mistakenly attacks healthy liver cells. It is not caused by a virus, it is not contagious, and it is not the result of anything you drank, ate or caught. The purpose of treatment is to calm the immune attack, reduce inflammation inside the liver, prevent scarring and protect liver function over the long term. With an accurate diagnosis, the right medication and careful follow-up, many people control the disease and maintain a good quality of life.

For many people, the diagnosis comes as a surprise. Symptoms can be vague or absent, blood tests may be abnormal for reasons that are not immediately obvious, and the word “hepatitis” raises understandable worries about infection, cirrhosis and liver failure. It helps to separate the word from its associations. Hepatitis — hepatită, hépatite and its equivalents in other languages — simply means inflammation of the liver. It says nothing about the cause. Viral infection is one cause. An immune system that has turned on its own liver is another, and that is what this page is about.

You will see the condition abbreviated in different ways. Clinicians and medical papers usually shorten it to AIH; online you may also come across the informal shorthand “AI hep”. All of these refer to the same condition, and all of them are distinct from viral hepatitis, which has different causes, different tests and different treatments. Confusing the two leads to unnecessary fear — of contagion, of stigma, of the wrong prognosis — so the distinction is worth stating plainly at the start.

What is autoimmune hepatitis?

Autoimmune hepatitis is a condition in which the body’s immune defences, which normally target infections, misidentify liver cells as a threat and attack them. The result is ongoing inflammation. Left uncontrolled, that inflammation gradually replaces healthy liver tissue with scar tissue — a process called fibrosis — which can progress to cirrhosis and, eventually, to loss of liver function. Controlled early and consistently, the inflammation can often be brought into remission before serious scarring develops.

Doctors describe two main types. Type 1 is the more common form, can appear at any age and is associated with antinuclear antibodies and anti-smooth muscle antibodies in the blood. Type 2 is rarer, tends to appear in childhood or adolescence and is associated with a different antibody pattern. The distinction matters mainly for diagnosis and monitoring; the treatment principles are broadly similar. Autoimmune hepatitis is also more common in women than in men, although men certainly develop it, and it occurs across all ethnic backgrounds.

Is autoimmune hepatitis contagious?

No. Autoimmune hepatitis is not contagious in any circumstance. You cannot pass it on through food, water, touch, kissing, sexual contact, blood or childbirth, and you cannot catch it from someone who has it. This is a fundamental difference from viral forms of the disease: hepatitis A spreads through contaminated food and water, and hepatitis B and C spread through blood and body fluids. Autoimmune hepatitis has no infectious agent at all — the problem originates inside the patient’s own immune system. Family members, partners and colleagues are at no risk from contact, and no isolation or hygiene precautions are needed because of the diagnosis itself.

How rare is autoimmune hepatitis?

Autoimmune hepatitis is an uncommon disease. It is rare enough that many general practitioners see only a handful of cases across a career, and rare enough that it is frequently mistaken at first for more common liver problems such as fatty liver disease or medication-related liver injury. It is not, however, so rare that specialists lack experience with it: hepatology units diagnose and manage it regularly, and the diagnostic criteria and treatment protocols are well established internationally. The practical consequence of its rarity is that patients often benefit from assessment by physicians who focus on liver disease, because the condition is easy to miss and easy to misattribute.

What Causes Autoimmune Hepatitis?

What causes autoimmune hepatitis is not fully understood, but the accepted picture is a combination of genetic predisposition and an environmental trigger. Some people carry immune-system genes that make them more prone to autoimmune reactions in general. In a small proportion of those people, something — often never identified — sets off an immune response that targets the liver and then fails to switch itself off. The disease is therefore best understood as bad luck layered on inherited susceptibility, not as the consequence of anything the patient did.

How do you get autoimmune hepatitis?

You do not “get” autoimmune hepatitis from any external source, and you cannot acquire it from another person. The condition develops when a genetically susceptible immune system loses tolerance to the body’s own liver cells. It is not inherited in a simple pattern — having a relative with the disease does not mean you will develop it — although autoimmune conditions of various kinds do cluster in some families. It is also not caused by alcohol, diet, weight or lifestyle, which is a point worth emphasising because patients with any form of hepatitis often encounter unfair assumptions. Blood tests can readily distinguish autoimmune hepatitis from alcohol-related and metabolic liver disease.

What can trigger autoimmune hepatitis?

Several triggers have been linked to the onset of autoimmune hepatitis in susceptible people, although in most individual cases no trigger is ever identified. Viral infections are one suspected trigger: some patients date their first symptoms to an illness weeks or months earlier. Certain medicines — including some antibiotics — and some herbal supplements have been associated with an autoimmune-hepatitis-like liver injury, which is one reason your doctors will ask in detail about everything you have taken, prescribed or otherwise. Other autoimmune diseases frequently coexist with AIH, suggesting a shared underlying tendency rather than a single cause. What all of these have in common is that the trigger starts a process the immune system then continues on its own; removing the trigger does not, by itself, end the disease.

It follows that there is no known way to prevent autoimmune hepatitis, and no reason for self-blame after a diagnosis. The useful questions are forward-looking: how active is the inflammation, how much scarring exists already, and what treatment plan will protect the liver from here on.

Autoimmune Hepatitis Symptoms

Autoimmune hepatitis symptoms range from nothing at all to sudden, obvious jaundice — and this variability is one of the reasons the disease is often diagnosed late. Many patients are identified only because a routine blood test shows elevated liver enzymes. Others feel unwell for months without a clear explanation. Neither pattern is more “real” than the other; silent inflammation damages the liver just as effectively as symptomatic inflammation.

When symptoms do occur, the most common include:

• Persistent fatigue, often out of proportion to daily activity
• Reduced appetite, nausea or a general feeling of being unwell
• Discomfort or a dull ache in the upper right abdomen
• Joint pain, sometimes moving between joints
• Itching of the skin
• Dark urine and pale stools
• Yellowing of the skin and eyes (jaundice)
• Menstrual irregularity, unexplained weight loss or general weakness

In more advanced disease, signs of chronic liver damage may appear: swelling of the abdomen or legs from fluid retention, easy bruising or bleeding, small spider-like blood vessels on the skin, and episodes of confusion related to impaired liver function. These findings suggest that significant scarring may already be present and change how the condition is investigated and monitored.

Symptoms alone can neither confirm nor exclude autoimmune hepatitis. Fatigue and nausea have hundreds of causes; jaundice has dozens. What symptoms do is guide the urgency and direction of testing. Persistent, unexplained liver-test abnormalities — with or without symptoms — warrant proper specialist evaluation, because the earlier active inflammation is identified, the more liver there is left to protect.

How does autoimmune hepatitis affect the body?

Autoimmune hepatitis affects the body primarily through the liver, but its reach is wider than one organ. In the liver itself, immune cells infiltrate the tissue and attack hepatocytes, releasing the enzymes that show up as abnormal blood tests. Over time, repeated injury and repair lay down scar tissue, which stiffens the liver, obstructs blood flow through it and can raise pressure in the portal vein — the source of complications such as fluid accumulation and enlarged veins in the oesophagus. Beyond the liver, the same immune dysregulation can produce joint pain, skin changes and profound fatigue, and it frequently coexists with other autoimmune diseases affecting the thyroid, gut, joints or kidneys. The liver’s central role in producing proteins, clotting factors and bile means that advanced disease can affect nutrition, blood clotting and hormone balance throughout the body. All of this is the argument for treating the inflammation rather than watching it.

How Autoimmune Hepatitis Is Diagnosed

Diagnosis rests on a pattern of findings rather than a single test. It usually begins with blood work: liver enzymes (which reflect active cell injury), bilirubin, albumin, a clotting profile, a complete blood count and immunoglobulin G, which is characteristically elevated in autoimmune hepatitis. Alongside these, physicians test for autoantibodies — antinuclear antibodies, anti-smooth muscle antibodies and, in suspected type 2 disease, anti-LKM1 antibodies. These results are always interpreted in context. A positive antibody test alone does not establish the diagnosis, because low levels of these antibodies occur in healthy people and in other diseases; equally, a negative test does not exclude AIH. The full pattern is what matters.

An essential part of the workup is ruling out conditions that mimic autoimmune hepatitis. That means testing for viral causes, including hepatitis B and hepatitis C, and assessing for alcohol-related liver disease, fatty liver disease, medication-related liver injury, metabolic and genetic liver disorders, and bile duct disease. Several of these can coexist with AIH, which is why the exclusion step is done systematically rather than assumed.

Imaging examines the liver’s structure rather than its chemistry. Ultrasound is the usual starting point, assessing liver texture, spleen size, blood flow and any fluid in the abdomen. Elastography — a specialised, non-invasive scan — estimates liver stiffness, which reflects the degree of fibrosis, although it does not replace other forms of assessment. Computed tomography or magnetic resonance imaging may be added when bile duct disease, vascular problems or focal liver lesions need clarification.

A liver biopsy is recommended in many cases: when the diagnosis is uncertain, when disease severity needs staging, or when another liver condition may be present at the same time. The procedure is performed with image guidance and local anaesthesia, and is planned with particular care in patients with abnormal clotting tests, low platelet counts or suspected advanced disease. A pathologist then examines the tissue for the characteristic features of AIH — interface hepatitis, plasma cell infiltration — and grades how much inflammation and scarring are present. That staging information directly shapes treatment intensity and follow-up.

For patients diagnosed elsewhere, a structured second opinion often centres on re-reviewing existing evidence: prior biopsy slides, laboratory trends over time, imaging files and medication history. Re-reading a biopsy or re-plotting enzyme trends can confirm the diagnosis, sharpen the staging, or occasionally overturn a label that never quite fitted — each of which changes what long-term treatment should look like.

Autoimmune Hepatitis Treatment: How It Works

Autoimmune hepatitis treatment is a structured medical approach designed to confirm the diagnosis, suppress the harmful immune activity, control liver inflammation, prevent progression to fibrosis or cirrhosis, and watch for relapse over time. It is medication-based — there is no operation that treats AIH itself — and it is a continuing process rather than a single prescription. A typical treatment pathway moves through five phases:

1. Confirmation and staging. The team verifies the diagnosis, excludes mimicking conditions and establishes how much inflammation and scarring exist.
2. Induction of remission. Medication — usually corticosteroids first — brings active inflammation under control.
3. Transition to maintenance. A steroid-sparing immunosuppressant, most commonly azathioprine, is introduced or continued while the steroid dose is gradually reduced.
4. Monitoring. Regular blood tests track liver enzymes, bilirubin, blood counts, kidney function and medication safety.
5. Long-term planning. The team maintains remission on the lowest effective medication burden and, in selected patients after prolonged stability, may discuss whether cautious treatment withdrawal is realistic.

Corticosteroids act quickly against active inflammation, which is why they are usually the first step in patients with clearly active disease. They also carry recognisable side effects — weight gain, mood changes, raised blood sugar, raised blood pressure, bone thinning, increased infection risk — which is why the strategy from the outset is to use them to gain control and then reduce them according to a structured tapering plan. Sudden discontinuation is avoided, both because relapse can occur and because the body needs time to adjust after steroid exposure. All dosing and tapering decisions belong to the treating physician; the schedule is individualised, not generic.

Steroid-sparing medication carries the longer-term work. These drugs maintain disease control while limiting cumulative steroid exposure, and they too require monitoring — of blood counts, liver tests and tolerance. The exact regimen depends on disease severity, liver function, other medical conditions, pregnancy considerations, previous response to treatment and whether cirrhosis is present. Two patients with the same diagnosis may quite rightly leave with different plans.

The measurable goal of treatment is biochemical remission: liver enzymes and immunoglobulin G returning to normal or near-normal levels. In selected situations, physicians also assess whether the inflammation has settled within the liver tissue itself, since blood tests can occasionally look better than the tissue does. Reaching remission can take weeks to months; symptoms such as fatigue sometimes lag behind the laboratory improvement, which is normal and does not mean treatment is failing.

Not everyone responds to first-line therapy as expected. When response is incomplete, the team works through a checklist rather than simply increasing doses: is the diagnosis right, is the medication being taken and absorbed, is the dose adequate, is an overlap condition present, is a second liver disease contributing? Some patients need second-line immunosuppressants. A smaller group has genuinely difficult-to-control disease, significant medication intolerance or advanced liver damage at diagnosis; these situations call for more specialised planning, and in rare cases evaluation for liver transplantation becomes part of the conversation. Even then, early specialist involvement clarifies options and reduces avoidable risk.

Supportive care runs alongside the medication. Patients are generally advised to avoid alcohol unless their physician gives specific guidance, and every prescription, over-the-counter product and supplement is worth reviewing with the treating team, because some — herbal products in particular — can worsen liver injury or interact with therapy. Vaccination status is reviewed, bone health is protected during steroid treatment, and nutrition counselling can help where weight change, diabetes risk, fluid retention or cirrhosis complicates the picture. A good treatment plan is one that remains workable in daily life, not just on paper.

Will autoimmune hepatitis go away?

Usually not on its own, and usually not permanently. Autoimmune hepatitis is a chronic condition: treatment can bring it into remission — often complete, sustained remission — but the underlying immune tendency remains. Many patients need long-term maintenance therapy, sometimes for many years. In a subset of patients with prolonged, stable remission, physicians may cautiously discuss withdrawing treatment, typically after an extended period of normal laboratory values and sometimes after reassessing inflammation in the liver tissue. Even after successful withdrawal, relapse is possible and monitoring continues, because relapse is often silent at first, visible only in blood tests. The honest framing is this: AIH is rarely something you are finished with, but it is very often something you can live well with under control.

Who Needs Evaluation for Autoimmune Hepatitis

Autoimmune hepatitis can affect people of any age and background. It is more common in women, but men develop it too, and it occurs in children as well as adults. Evaluation is appropriate when liver-test abnormalities are persistent or unexplained, when symptoms suggest ongoing liver inflammation, or when a previous diagnosis needs confirmation or restaging.

Treatment itself is generally indicated in patients with active disease: significant liver enzyme elevation, elevated immunoglobulin G, compatible autoantibody findings, symptoms of ongoing inflammation, or biopsy findings consistent with AIH. Not every abnormal test carries the same meaning, and not every patient carries the same risk, so the decision to treat — and how intensively — is individualised. Some patients present acutely, with rapidly rising enzymes and jaundice over a short period; others have quietly active disease that has smouldered for years before anyone connected the findings. Both groups need assessment, but the tempo and the medication strategy differ.

A separate group seeking evaluation are patients already on treatment whose disease is not behaving as expected — enzymes that will not normalise, repeated relapses, or side effects that make the current regimen hard to sustain. For them, the question is less “do I have AIH?” than “is my AIH being managed in the best available way?”, and a structured review of diagnosis, staging and medication history is usually where the answer begins.

Overlap Syndromes and Related Conditions

Autoimmune hepatitis does not always travel alone. It can overlap with other immune-mediated liver diseases, particularly primary biliary cholangitis and primary sclerosing cholangitis. These overlap syndromes matter because bile duct disease and liver-cell inflammation behave differently: they need different tests, sometimes combined medication strategies, and different long-term monitoring. Distinguishing pure AIH from an overlap syndrome is one of the more consequential judgements in the diagnostic workup, and one of the more common reasons a second pathology review changes a treatment plan.

Patients with AIH also carry a higher likelihood of other autoimmune conditions — thyroid disease, inflammatory bowel disease, coeliac disease, rheumatoid arthritis, type 1 diabetes, autoimmune skin conditions and immune-mediated kidney disease, the territory of autoimmune nephrology. Care therefore often involves coordination with endocrinology, rheumatology, gastroenterology, dermatology or nephrology, so that treatments for one condition do not undermine another.

Pregnancy deserves specific planning. For women who are pregnant, planning pregnancy or breastfeeding, disease control before and during pregnancy is important, and medication decisions must weigh both maternal liver health and fetal safety. These situations are best managed jointly by hepatology and maternal-fetal medicine, with the plan made before conception where possible.

Finally, medication intolerance is itself an indication for expert care. Corticosteroids and immunosuppressants can cause weight gain, mood changes, high blood sugar, high blood pressure, bone thinning, infection susceptibility, gastrointestinal discomfort and changes in blood counts. The task is to control the liver disease while minimising harm from the treatment — which requires monitoring, thoughtful dose adjustment and sometimes a change of drug, not perseverance with a regimen that is doing damage of its own.

Why Acting Early Matters

Autoimmune hepatitis is treatable, but uncontrolled inflammation injures the liver cumulatively. When the immune attack continues unchecked, healthy tissue is progressively replaced by scar, and scarring can advance to cirrhosis, portal hypertension, liver failure and — in patients with cirrhosis — an increased risk of liver cancer. The window that matters is the one before advanced scarring: inflammation is often reversible, established cirrhosis largely is not. Patients who start appropriate therapy before cirrhosis develops generally preserve more liver function; even when cirrhosis is already present, controlling inflammation reduces further injury and can improve stability.

Delay also complicates the picture in practical ways. Worsening jaundice, clotting problems, fluid accumulation and variceal bleeding turn a manageable outpatient condition into an urgent one, and layered medication effects make the diagnosis harder to read. Acting early does not mean rushing onto immunosuppression without evidence. It means completing the right evaluation promptly, interpreting the results accurately, and starting treatment when the balance of benefit and risk genuinely supports it — a balance best judged within a structured hepatology pathway.

What is the life expectancy of someone with autoimmune hepatitis?

For many people whose disease is diagnosed before advanced scarring and who respond to treatment, the outlook is good, and long, active lives are the norm rather than the exception. Life expectancy depends chiefly on the stage of liver disease at diagnosis, the response to immunosuppressive therapy, and the consistency of long-term monitoring. Patients diagnosed after cirrhosis has developed face more complications and need closer surveillance, though treatment still matters at that stage. No responsible clinician offers a single number here, because the honest answer is individual: it is written by staging, response and follow-up, not by the diagnosis alone. That is precisely why early evaluation and sustained treatment carry so much weight.

Benefits of Autoimmune Hepatitis Treatment

The benefits of treatment depend on disease stage, response to medication and consistency of follow-up, but the goals are clear: reduce liver inflammation and protect long-term liver health.

Benefit	What It Means for You
Control of liver inflammation	Medication can reduce the immune attack on liver cells, helping liver enzymes improve and symptoms such as fatigue or jaundice lessen over time.
Lower risk of disease progression	Effective treatment may reduce ongoing fibrosis and help prevent progression toward cirrhosis or liver failure.
Personalised medication planning	Your regimen can be adjusted for disease severity, side effects, pregnancy plans, other illnesses and previous response to therapy.
Monitoring for relapse and complications	Regular follow-up identifies relapse early and supports screening for cirrhosis-related complications when needed.
A clear long-term picture	A confirmed diagnosis and structured care plan let you manage the condition confidently with your local physicians at home.

Recovery and Follow-Up Timeline

Recovery in autoimmune hepatitis is measured by symptom improvement, laboratory response, medication tolerance and durable disease control — not by a single treatment date. The pattern below is typical, though individual timelines vary.

Time Period	What Patients Can Expect
Day 1	Evaluation begins with review of records, examination, laboratory testing and planning of imaging or biopsy if needed. If the diagnosis is clear and disease is active, treatment may be started or adjusted.
First week	Additional test results are reviewed. Patients receive guidance on medications, side effects, diet, alcohol avoidance, infection precautions and follow-up testing.
First month	Liver enzymes and symptoms often begin to improve in responsive patients. Doses may be reassessed, and safety monitoring continues.
Three to six months	The care team assesses whether remission is being achieved. Steroid doses may be tapered gradually and maintenance therapy optimised.
Longer term	Periodic monitoring continues for relapse, medication effects, fibrosis status and cirrhosis-related risks if present. Some patients remain on long-term maintenance treatment.

Factors That Influence Outcomes

The single most important factor is the stage of liver disease at diagnosis. Patients treated before advanced fibrosis or cirrhosis develops have more liver reserve and fewer complications; patients with established cirrhosis still benefit from controlling inflammation, but their monitoring is more intensive and their margin for error smaller.

Response to immunosuppressive therapy comes next. Many patients respond well to standard treatment, but some have an incomplete response, relapse after improvement, or cannot tolerate the medication. Good outcomes in these groups come from careful reassessment — of the regimen, the diagnosis and possible overlap conditions — rather than from any single decision made at the start of treatment.

Adherence is decisive and easy to underestimate. AIH can improve dramatically on therapy, and feeling well creates a natural temptation to drift from the plan. Relapse after early or unplanned treatment withdrawal is well recognised, and it is often silent at first, showing only in blood tests. This is why scheduled monitoring continues even when everything feels fine, and why any change to the regimen is a decision for the treating doctor rather than something to trial at home.

Diagnostic accuracy shapes everything downstream. Some patients referred with an AIH label actually have fatty liver disease, drug-induced liver injury, viral hepatitis, biliary disease — or more than one condition at once. Treating the wrong disease exposes a patient to immunosuppression risks while the real problem progresses. A structured diagnostic pathway, including pathology review where needed, is the protection against this.

Coexisting health conditions influence medication choices and monitoring frequency. Diabetes, osteoporosis, hypertension, obesity, kidney disease, inflammatory bowel disease, thyroid disease, pregnancy and infection risk all bear on the plan; steroid exposure, for instance, demands attention to blood sugar, bone protection, mood and blood pressure. A sound plan considers the whole patient, not only the liver enzyme numbers.

Where cirrhosis is present, the follow-up strategy widens: screening for oesophageal varices, surveillance for liver cancer, monitoring for fluid retention and periodic assessment of overall liver function. If liver function declines severely despite treatment, transplant evaluation may enter the discussion. This is not the typical path — most patients never approach it — but access to advanced liver expertise matters most precisely when disease is complex.

Finally, everyday safety measures support everything else: avoiding alcohol, maintaining a healthy weight, keeping vaccinations current, and reviewing every medicine and supplement with the treating team, since some products sold as harmless can injure the liver or interact with therapy.

How Acibadem Approaches Autoimmune Hepatitis Care

At Acibadem, care for autoimmune hepatitis is built around careful evaluation, evidence-based treatment protocols and long-term liver monitoring. Because the condition sits at the junction of several disciplines, hepatology, gastroenterology, radiology, laboratory medicine, pathology and — where relevant — transplant medicine may all contribute to a single patient’s plan. Each link in that chain has to be reliable: blood tests interpreted correctly, imaging designed to answer the right clinical question, biopsy tissue read with experience, and medication monitored consistently.

Complex cases may be discussed in multidisciplinary settings, which is particularly valuable when the diagnosis is uncertain, when AIH overlaps with bile duct disease, when cirrhosis is present, or when previous treatment has not achieved adequate control. A multidisciplinary discussion does not replace the relationship between patient and physician; it brings additional expertise to a difficult question and then hands the answer back to that relationship.

The diagnostic pathway can draw on advanced laboratory testing, high-resolution imaging, elastography for non-invasive fibrosis assessment, image-guided biopsy when needed and detailed pathology review. The point of the technology is precision, not complexity: a clearer diagnosis, better staging of liver health, and a treatment plan built on the actual pattern of disease rather than assumptions carried over from earlier care.

For patients travelling from abroad, practical coordination matters as much as the medicine. Acibadem International provides support in more than 20 languages, helping patients communicate with clinical teams, organise appointments, share medical records and understand each step of care. Continuity after travel is treated as part of the treatment itself: because AIH requires long-term monitoring, the care plan is written to be usable by the patient’s local physician — medication names and doses, tapering schedules, laboratory monitoring intervals, warning signs and clear criteria for specialist re-involvement. A well-prepared handover is what prevents an international visit from becoming a gap in care.

Second opinions are a recognised part of this work. A structured second opinion can confirm that autoimmune hepatitis is the correct diagnosis, judge whether treatment intensity fits the disease activity, restage fibrosis, or investigate why liver tests remain abnormal despite therapy. In most cases the aim is not to replace an existing doctor, but to add clarity and confidence to a plan the patient will live with for years.

Living Well With Autoimmune Hepatitis

An AIH diagnosis can feel overwhelming, particularly when the symptoms were vague and the treatment involves long-term immune-suppressing medication. The condition becomes far more manageable once two things are settled: an accurate diagnosis and an honest picture of the liver’s current state. From there, treatment can be planned deliberately, monitored consistently and adjusted as the body responds.

Patients who do well over the long term tend to share habits worth naming. They keep their own copies of laboratory results, imaging reports, biopsy findings and medication history, so that any physician they see can read the trend rather than a single snapshot. They keep monitoring appointments even when they feel entirely well, because relapse announces itself in blood tests before it announces itself in symptoms. And they treat their regimen as a live plan reviewed with their doctor, not a fixed prescription — because in autoimmune hepatitis, the quality of the follow-up is as important as the quality of the first decision.